Categories: DataDevelopmentDrugHealthTechInfrastructureLearnManagementPlatformScienceTechnology
Superluminal Medicines ACCELERATING NEW POSSIBILITIES IN DRUG DISCOVERY AND DEVELOPMENT Science Our Hyperloop™ Platform combines cutting-edge structure-based drug discovery with AI-powered computational methods and experimental validation to identify and develop small molecule therapeutics. Our Platform Pipeline Focusing initially on GPCRs, our pipeline blends scientific innovation with patient-centric precision to develop next-generation treatments for cardiometabolic diseases. […]
Investors 1
Funding Rounds 1
| Date | Series | Amount | Investors |
| 17.10.2024 | Series A | $120M | - |
Mentions in press and media 7
| Date | Title | Description |
| 03.09.2026 | Superluminal Medicines Raises $60M in Series B Funding | Superluminal Medicines, a Boston, MA-based biotechnology company integrating AI/ML, protein dynamics, and structural biology to generate G protein-coupled receptor (GPCR) targets, raised $60M in Series B financing.
The round was led by BVF ... |
| 17.10.2024 | Superluminal Medicines Nets $120M Series A |
BOSTON, MA, Superluminal Medicines announced the closing of a $120 million Series A funding round led by RA Capital.
>> Click here for more funding data on Superluminal Medicines
>> To export Superluminal Medicines funding data... |
| 09.09.2024 | Superluminal Medicines Closes $120M Series A Funding | Superluminal Medicines, a Boston, MA-based company that uses generative biology, chemistry and machine learning approaches to create medicines, raised $120M in Series A funding.
The round was led by RA Capital Management with participation ... |
| 09.09.2024 | Lilly-backed Superluminal raises $120M series A to bring membrane receptor drugs into the clinic | Just over a year after launching with $33 million in seed funding, Boston-based Superluminal Medicines is supercharging its small-molecule drug development with a $120 million series A round backed by the likes of Eli Lilly.
Superluminal fo... |
| 04.09.2023 | Superluminal Medicines Raises $33M in Seed Funding | Superluminal Medicines, a Boston, MA-based generative biology and chemistry company, raised $33M in Seed funding.
The round was led by RA Capital Management with participation from Insight Partners, NVIDIA, and Gaingels.
The company intends... |
| - | Superluminal Medicines | “Superluminal Medicines” |
| - | Superluminal Medicines | “Superluminal Medicines ACCELERATING NEW POSSIBILITIES IN DRUG DISCOVERY AND DEVELOPMENT Science Our Hyperloop™ Platform combines cutting-edge structure-based drug discovery with AI-powered computational methods and experimental validation ... |
Reviews 0
